The clinical trial, sponsored by The University of The West Indies, aims to evaluate the efficacy of Dibenzyl Trisulphide in patients with stage IV cancers, including breast, prostate, cervical, and colon cancers. Given the increasing demand for alternative cancer therapies, particularly in late-stage disease settings, this trial could position Dibenzyl Trisulphide as a novel treatment option. The market for cancer therapeutics is highly competitive, with numerous established players; however, if successful, this asset could fill a niche for patients seeking complementary or alternative treatments. Diligence should focus on the regulatory landscape, potential market access challenges, and the need for robust clinical data to support claims of efficacy and safety.